Entrada Therapeutics shareholders approve officer liability limitation amendment and elect director

Entrada Therapeutics, Inc.

Stockholders approved Certificate of Amendment to limit officer liability as permitted by Delaware law.
Gina Chapman elected as Class III director with 19,701,297 votes for, 101,960 withheld, 2,418,006 broker non-votes.
Ernst & Young LLP ratified as independent auditor for FY 2024 (22,210,935 for, 2,174 against, 8,154 abstain).
Certificate of Amendment filed with Delaware Secretary of State, effective June 13, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.